Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 1, 1998, Pages 33-44

  Vervloet, Marc G ^b   Thijs, Lambertus G ^a,b   Hack, C Erik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

Coagulation; Diffuse intravascular coagulation (DIC; Fibrinolysis; Sepsis; Septic shock

Indexed keywords

CYTOKINE; PLASMINOGEN ACTIVATOR; PROTEIN C; PROTEIN S; THROMBIN ANTITHROMBIN COMPLEX;

ARTICLE; BLOOD CLOTTING; COMPLEX FORMATION; CRITICAL ILLNESS; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HUMAN; MEDIATOR RELEASE; MICROVASCULATURE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SEPSIS; SEPTIC SHOCK;

EID: 0031929812     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995821     Document Type: Article

References (145)

1. Hesselvik JF, Blombäck M, Brodin B, Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989;17:724-733
2. Voss R, Matthias FR, Borkowski G, Reitz D. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 1990;75:99-105
3. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-823
4. Lorente JA, García-Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993;103:1536-1542
5. Kidokoro A, Iba T, Fukunaga M, Yagi Y. Alterations in coagulation and fibrinolysis during sepsis. Shock 1996;5:223-228
6. Levi M, ten Cate H, van der Poll T, van Deventer SJH. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975-979
7. Brandtzaeg P, Sandset PM, Joø GB, Øvstebo R, Abildgaard U, Kierulf P. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989;55:459-470
8. Fijnvandraat K, Derkx B, Peters M, et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemostas 1995;73:15-20
9. Ziegler KJ, Fisher CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-IA human monoclonal antibody against endotoxin. N Engl J Med 1991;324: 429-436
10. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 Murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266:1097-1102
11. Fisher CJ, Dhainaut JFA, Opal SM, et al. Recombinant human Interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994;271:1836-1843
12. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. JAMA 1995;273: 934-941
13. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995;23:994-1005
14. Cohen J, Carlet J, Intersept study group. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996;24:1431-1440
15. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117-123
16. Taylor Jr FB, Chang A, Ruf W, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991;33:127-134
17. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-120
18. Biemond BJ, ten Cate H, Levi M, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemostas 1995;73:223-230
19. Creasey AA, Chang ACK, Feigen L, Wün TC, Taylor Jr FB, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91:2850-2860
20. Carr C, Bild GS, Chang ACK, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gram-negative model of septic shock. Circ Shock 1995;44:126-137
21. Van Deventer SJH, Büller HR, Ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimemal endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990;76:2520-2526
22. Levi M, ten Cate H, Bauer EKA, Büller HR, ten Cate JW, Rosenberg RD. Dose-dependent endotoxin-induced cytokine release and coagulation activation in chimpanzees. Thromb Haemostas 1991;65:793
23. Pixley RA, DeLa Cadena R, Page JD, et al. The contact system contributes to hypotension but not to disseminated intravascular coagulation in lethal bacteremia. J Clin Invest 1993; 91:61-68
24. Ten Cate H, Brandjes DPM, Wolters HJ, Van Deventer SJH. Disseminated intravascular coagulation: pathophysiology, diagnosis, and treatment. New Horizons 1993;1:312-323
25. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989;9:2752-2755
26. Østerud B, Flægstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemostas 1983; 49:5-7
27. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987;79:124-130
28. Colucci M, Balconi G, Lorenzet R, et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983;71:1893-1896
29. Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984;63:1338-1347
30. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992;326:800-806
31. Wada H, Minamikawa K, Wakita Y, et al. Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1993;43:190-194
32. Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984;74:341-350
33. Kobayashi M, Shimada K, Ozawa T. Human recombinant interleukin 1-beta and tumor necrosis factor alfa-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990;144:383-390
34. Hung DT, Vu TKH, Wheaton VI, Ishii K, Coughlin SR. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J Clin Invest 1992;89:1350-1353
35. Harris KW, Esmon CT. Protein S is required for bovine platelets to support activated protein C binding and activity. J Biol Chem 1985;260:2007-2011
36. Marlar RA, Griffin JH. Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest 1980;66:1186-1189
37. 1-antitrypsin. J Biol Chem 1988;263: 11613-11616
38. Saeki T, Hirose S, Nukatsuka M, Kusunoki Y, Nagasawa S. Evidence that C4b-binding protein is an acute phase protein. Biochem Biophys Res Commun 1989;164:1446-1451
39. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemostas 1991;66:6-15
40. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992;29:159-169
41. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989;338:518-520
42. Taylor Jr FB, Emerson Jr TE, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988;26:227-235
43. Taylor Jr FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in baboons. J Clin Invest 1987;79:918-925
44. Taylor F, Chang A, Ferrel G, et al. C4b-binding protein exacerbates the host response to Escherichia coli. Blood 1991;78: 357-363
45. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997;66:101-195
46. Hesse DG, Tracey KJ, Fong Y, et al. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet 1988;166:147-153
47. Mastich GD, Danner RL, Ceska M, Suffredini AF. Detection of interleukin-8 and tumor necrosis factor in normal humans following intravenous endotoxin: the effect of anti-inflammatory agents. J Exp Med 1991;173:1021-1024
48. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin-1β and interleukin-6 appearance during lethal bacteremia. J Exp Med 1989;170:1627-1633
49. Redl H, Schlag G, Bahrami S, Schade U, Ceska M, Stütz P. Plasma neutrophil-activating peptide-1/interleukin-8 and neutrophil elastase in a primate bacteremia model. J Infect Dis 1991;164:383-388
50. Van der Poll T, Levi M, van Deventer SJH, et al. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994;83:446-451
51. Van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994;179:1253-1259
52. Fischer E, Marano MA, van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89: 1551-1557
53. Van der Poll T, van Deventer SJH, Hack CE, et al. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992;79:693-698
54. Van Deventer SJH, Hart M, van der Poll T, Hack CE, Aarden LA. Endotoxin and tumor necrosis factor-α-induced interleukin-8 release in humans. J Infect Dis 1993;167:461-464
55. De Boer JP, Creasy AA, Chang A, et al. Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock 1993;39:59-67
56. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984;160:618-623
57. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986;163: 740-745
58. Bevilacqua MP, Pober JS, Majeau GR, Fiers RW, Cotran RS, Gimbrone Jr MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 1986;83:4533-4537
59. Conway EM, Back R, Rosenberg RD, Koningsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989;52:231-241
60. Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis lactor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988;72: 128-133
61. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA 1986;83:3460-3464
62. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine endothelial cells in culture. Blood 1989;73:159-165
63. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of thrombomodulin gene in endothelial cells. Mol Cell Biol 1988;8:5588-5592
64. Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-α: comparison of transcriptional and posttranscriptional mechanism. Blood 1991;77:542-550
65. Hooper WC, Phillips DJ, Ribeiro MJA, et al. Tumor necrosis factor-α downregulates protein S secretion in human microvascular and umbilical vein endothelial cells but not in the HepG-2 hepatoma cell line. Blood 1994;84:483-489
66. Van der Poll T, Büller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990;322:1622-1627
67. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989;74:165-172
68. Van der Poll T, van Deventer SJH, Büller HR, Sturk A, ten Cate JW. Comparison of the early dynamics of coagulation activation after injection of endotoxin and tumor necrosis factor in healthy humans. Prog Clin Biol Res 1991;367:55-60
69. Hinshaw LB, Tekamp-Olson P, Chang ACK, et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF). Circ Shock 1990;30: 279-292
70. Taylor Jr FB. Studies on the inflammatory-coagulant axis in the baboon response to E. coli: regulatory roles of protein C, S, C4bBP and of inhibitors of tissue factor. Prog Clin Biol Res 1994;388:175-194
71. 2 in sepsis: Studies in nonhuman primates after interleukin-1α administration and during lethal bacteremia. Blood 1995;86:1027-1034
72. Boermeester MA, van Leeuwen PAM, Coyle SM, Wolbink GJ, Hack CF, Lowry SF. Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. Arch Surg 1995;130:739-748
73. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercelotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-520
74. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996;88:881-886
75. Leclerc F, Hazelzet J, Jude B, et al. Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med 1992;18:202-205
76. Thijs LG, de Boer JP, de Groot MCM, Hack CE. Coagulation disorders in septic shock. Intensive Care Med 1993;19:S8-S15
77. Takahashi H, Tatewaki W, Wada K, Hanano M, Shibata A. Thrombin versus plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. Am J Hematol 1990;33:90-95
78. Hesselvik JF, Malm J, Dahlbäck B, Blombäck M. Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemostas 1991;65:126-129
79. Wuillemin WA, Fijnvandraat K, Derkx BHF, et al. Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock. Thromb Haemostas 1995;74: 1436-1441
80. Alcaraz A, España F, Sánchez-Cuenca J, et al. Activation of the protein C pathway in acute sepsis. Thromb Res 1995;79: 83-93
81. Philippé J, Offner F, Declerck PJ, et al. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemostas 1991;65:291-295
82. Smith-Erichsen N, Aasen AO, Gallimore MJ, Amundsen E. Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock 1982;9:491-497
83. 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature 1985;317:730-732
84. Jordan RE, Nelson RM, Kilpatrick J, Newgren JO, Esmon PC, Fournel MA. Inactivation of human antithrombin by neutrophil elastase. Kinetics of the heparin-dependent reaction. J Biol Chem 1989;264:10493-10500
85. Fourrier F, Lestavel P, Chopin C, et al. Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 1990;16:121-124
86. Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985;66:59-63
87. Warr TA, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: II. Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 1989;74:994-998
88. Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 1974;140:797-802
89. Dela Cadena RA, Suffredini AF, Page JD, et al. Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 1993;91:3313-3317
90. Kalter HJ, Daha MR, ten Cate JW, Verhoef J, Bouma BN. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985;151:1019-1027
91. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, et al. Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood 1988;72:1841-1848
92. 2-Macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991;77:2660-2667
93. Citarella F, Felici A, Brouwer M, Wagstaff J, Fantoni A, Hack CE. Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood 1997;90:1501-1507
94. Pixley RA, DeLa Cadena RA, Page JD, et al. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 1992;140:897-906
95. Toda N, Okamura T. Endothelium-dependent and independent response to vasoactive substances of isolated human coronary artery. Am J Physiol 1992;262:H995-H999
96. Hong SL. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res 1980;18:787-791
97. Jansen PM, Pixley RA, Brouwer M, et al. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996;87:2337-2344
98. Francis CW, Marder VJ. Mechanisms of fibrinolysis. In: Williams WJ, ed. Williams Hematology, 5th ed. New York: 1995; 1252-1260
99. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381-387
100. Schleef RR, Loskutoff DJ. Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis 1988;18:328-341
101. Haj MA, Robbie LA, Adey GD, Bennett B. Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients. Thromb Haemostas 1995;74:1528-1532
102. Bick RL. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemostas 1996;22: 69-88
103. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989;320:1165-1172
104. Biemond BJ, Levi M, ten Cate H, et al. Plasminogen activator and plasminogen activator inhibitor 1 release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Science 1995;88:587-594
105. van der Poll T, Levi M, Büller HR, et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991;174:729-732
106. van Hinsbergh VW, Bauer KA, Kooistra T, et al. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990;76:2284-2289
107. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988;263: 5797-5803
108. Bevilacqua MP, Schleef RR, Gimbrone MA Jr, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 1986;78: 587-591
109. van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 1990;75:1991-1998
110. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987;109:97-104
111. Quax PH, van den Hoogen CM, Verheijen JH, et al. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem 1990;265:15560-15563
112. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991;88:1346-1353
113. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257:2912-2919
114. Giles AR, Nesheim ME, Herring SE, Hoogendoorn H, Stumb DC, Heldebrandt CM. The fibrinolytic potential of the normal primate following the generation of thrombin in vivo. Thromb Haemostas 1990;63:476-481
115. Levi M, Hack CE, de Boer JP, Brandjes DP, Buller HR, ten Cate JW. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest 1991;88:1155-1160
116. DeLa Cadena RA, Majluf-Cruz A, Stadnicki A, Agosti JM, Colman RW, Suffredini AF. Activation of the contact and fibrinolytic systems after intravenous administration of endotoxin to normal human volunteers: correlation with the cytokine profile. Immunopharmacology 1996;33:231-237
117. Mesters RM, Florke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemostas 1996;75:902-907
118. Haj MA, Neilly IJ, Robbie LA, Adey GD, Bennett B. Influence of white blood cells on the fibrinolytic response to sepsis: studies of septic patients with or without severe leukopenia. Br J Haematol 1995;90:541-547
119. Paramo JA, Fernandez Diaz FJ, Rocha E. Plasminogen activator inhibitor activity in bacterial infection. Thromb Haemostas 1988;59:451-454
120. Francis RB Jr, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations. J Lab Clin Med 1987;110:541-547
121. Asakura H, Jokaji H, Saito M, et al. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation. Am J Hematol 1991;36:176-183
122. Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990;57:271-278
123. Takahashi H, Hanano M, Takizawa S, Tatewaki W, Shibata A. Plasmin-alpha 2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation. Am J Hematol 1988;28:162-166
124. Asakura H, Jokaji H, Saito M, et al. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers. Blood Coag Fibrinolysis 1994;5:829-832
125. Kruithof EKO, Calandra T, Pralong G, et al. Evolution of plasminogen activator inhibitor type 1 in patients with septic shock - Correlation with cytokine concentrations. Fibrinolysis 1993;7:117-121
126. Okajima K, Yang WP, Okabe H, Inoue M, Takatsuki K. Role of leukocytes in the activation of intravascular coagulation in patients with septicemia. Am J Hematol 1991;36:265-271
127. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985;75:818-824
128. van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988;72: 1467-1473
129. Emeis JJ, Kooistra T. Interleukin-1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986;163: 1260-1266
130. Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986;77:165-169
131. Kugiyama K, Sakamoto T, Misumi I, et al. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 1993;73:335-343
132. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states [published erratum appears in Proc Natl Acad Sci USA 1992;89(3):1148]. Proc Nat Acad Sci USA 1991;88:9959-9963
133. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in post-menopausal women. N Engl J Med 1997;336:683-690
134. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991;266:2459-2465
135. Pralong G, Calandra T, Glauser MP, et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemostas 1989;61:459-162
136. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemostas 1996;75:224-228
137. Saito M, Asakura H, Jokaji H, et al. Haemostatic and fibrinolytic parameters in septic patients with leukopenia or leukocytosis. Eur J Haematol 1995;54:176-179
138. Kruithof EK, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987;70:1645-1653
139. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen that can be associated by denaturants. J Biol Chem 1989;260:11581-11587
140. Lindahl TL, Sigurdardoffir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemostas 1989; 62:748-751
141. Kruithof EKO. Plasminogen activator inhibitor type 1: biochemical, biological and clinical aspects. Fibrinolysis 1988; 2:59-70
142. Stief TW, Martin E, Caso F, Rodriquez JM. Oxidation susceptibility of plasminogen activator inhibitors in human plasma. Thromb Res 1990;60:177-180
143. Ono S, Mochizuli H, Tamakuma S. A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Am J Surg 1996;171:409-415
144. Idell S, James KK, Levin EG, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989;84:695-705
145. Bertozzi P, Astedt B, Zenzius L, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990;322:890-897.